Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Current Deferred Revenue (2021 - 2025)

Autolus Therapeutics (AUTL) has disclosed Current Deferred Revenue for 5 consecutive years, with $7.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Deferred Revenue fell 96.26% year-over-year to $7.6 million, compared with a TTM value of $7.6 million through Sep 2025, down 96.26%, and an annual FY2022 reading of $35.0 million, down 25.53% over the prior year.
  • Current Deferred Revenue was $7.6 million for Q3 2025 at Autolus Therapeutics, up from $2.1 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $203.4 million in Q3 2024 and bottomed at $2.1 million in Q2 2025.
  • Average Current Deferred Revenue over 5 years is $91.7 million, with a median of $47.0 million recorded in 2021.
  • The sharpest move saw Current Deferred Revenue skyrocketed 44.46% in 2024, then plummeted 98.93% in 2025.
  • Year by year, Current Deferred Revenue stood at $47.0 million in 2021, then decreased by 25.53% to $35.0 million in 2022, then skyrocketed by 302.29% to $140.8 million in 2023, then surged by 44.46% to $203.4 million in 2024, then crashed by 96.26% to $7.6 million in 2025.
  • Business Quant data shows Current Deferred Revenue for AUTL at $7.6 million in Q3 2025, $2.1 million in Q2 2025, and $4.7 million in Q1 2025.